The estimated Net Worth of Charles V. Iii Baltic is at least 488 千$ dollars as of 28 February 2023. Mr. Baltic owns over 81,500 units of MEI Pharma Inc stock worth over 319,365$ and over the last 12 years he sold MEIP stock worth over 0$. In addition, he makes 168,944$ as Independent Director at MEI Pharma Inc.
Sign up
Mr. Baltic MEIP stock SEC Form 4 insiders trading
Charles has made over 12 trades of the MEI Pharma Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently he bought 81,500 units of MEIP stock worth 18,745$ on 28 February 2023.
The largest trade he's ever made was buying 81,500 units of MEI Pharma Inc stock on 28 February 2023 worth over 18,745$. On average, Charles trades about 5,704 units every 156 days since 2012. As of 28 February 2023 he still owns at least 105,750 units of MEI Pharma Inc stock.
You can see the complete history of Mr. Baltic stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Charles Baltic biography
Charles V. Baltic III, J.D. serves as Independent Director of the Company. Mr. Baltic has been a Managing Director and Co-Head of Healthcare at Needham & Company since 2009. Prior to joining Needham, Mr. Baltic was a Managing Director and head of the biotechnology practice at CRT Capital Group from 2006 to 2008. From 2001 to 2006, he served as a Managing Director in Healthcare Investment Banking at Wachovia Securities. Prior to Wachovia, he was with Healthcare Investment Banking at Cowen and Company for six years, ultimately serving as a Director in Healthcare Investment Banking. Prior to beginning his investment banking career in 1996, Mr. Baltic practiced corporate and securities law with the firm of Dewey Ballantine, representing numerous healthcare and securities clients. Mr. Baltic is a Director of SIDIS Corp., a life sciences investment company. Mr. Baltic was a founding Trustee of the non-profit Hope Funds for Cancer Research, serving from 2007 to 2017 in that capacity, and remains on the Council of Advisors. Mr. Baltic was also a Director of the non-profit trade association Life Science Washington (formerly the Washington Biotechnology and Biomedical Association), serving from 2013 to 2018, and a member of the U.S. Securities and Exchange Commission’s Advisory Committee on Small and Emerging Growth Companies, serving from 2013 to 2015, and a Director of MedVantage Inc., which was ultimately acquired by IMS Health in 2011. Mr. Baltic earned his B.A and J.D. degrees from Georgetown University and M.B.A. degree in Finance from the Wharton School of the University of Pennsylvania.
What is the salary of Charles Baltic?
As the Independent Director of MEI Pharma Inc, the total compensation of Charles Baltic at MEI Pharma Inc is 168,944$. There are 9 executives at MEI Pharma Inc getting paid more, with Daniel Gold having the highest compensation of 1,854,410$.
How old is Charles Baltic?
Charles Baltic is 58, he's been the Independent Director of MEI Pharma Inc since 2011. There are 9 older and 4 younger executives at MEI Pharma Inc. The oldest executive at MEI Pharma Inc is Kevan Clemens, 75, who is the Independent Director.
What's Charles Baltic's mailing address?
Charles's mailing address filed with the SEC is C/O MEI PHARMA INC., 11455 EL CAMINO REAL, SUITE 250, SAN DIEGO, CA, 92130.
Insiders trading at MEI Pharma Inc
Over the last 12 years, insiders at MEI Pharma Inc have traded over 26,282,680$ worth of MEI Pharma Inc stock and bought 597,450 units worth 2,541,200$ . The most active insiders traders include Ventures Vii, Llc Vivo Vent...、Leaf Ventures Ii, L.P.New L...、Josiah T Austin. On average, MEI Pharma Inc executives and independent directors trade stock every 91 days with the average trade being worth of 360,383$. The most recent stock trade was executed by Funds Management Lp Anson A... on 22 September 2023, trading 48,060 units of MEIP stock currently worth 329,211$.
What does MEI Pharma Inc do?
mei pharma (nasdaq: meip) is a san diego-based oncology company focused on the clinical development of novel therapies for cancer. our lead drug candidate is pracinostat, a potential best-in-class, oral hdac inhibitor that has been granted breakthrough therapy designation from the fda in combination with azacitidine for the treatment of patients with newly diagnosed aml who are ≥75 years of age or unfit for intensive chemotherapy. our pipeline of drug candidates also includes me-401 (formerly pwt143), a next-generation oral pi3k delta inhibitor, and me-344, a novel mitochondrial inhibitor. for more, please go to www.meipharma.com.
What does MEI Pharma Inc's logo look like?
Complete history of Mr. Baltic stock trades at MEI Pharma Inc
MEI Pharma Inc executives and stock owners
MEI Pharma Inc executives and other stock owners filed with the SEC include:
-
Daniel Gold,
President, Chief Executive Officer, Director -
David Urso,
Chief Operating Officer, General Counsel -
Dr. Daniel P. Gold,
Pres, CEO & Director -
Brian Drazba,
Chief Financial Officer, Secretary -
David M. Urso B.A., Esq., J.D.,
COO & Gen. Counsel -
Robert Mass,
Chief Medical Officer -
Brian G. Drazba B.A., CPA, CPA,
CFO & Sec. -
Dr. Richard G. Ghalie,
Chief Medical Officer -
Dr. Robert D. Mass,
Strategic Advisor -
Charles Baltic,
Independent Director -
Nicholas Glover,
Independent Director -
Kevan Clemens,
Independent Director -
Frederick Driscoll,
Independent Director -
Tamar Howson,
Independent Director -
Cheryl Cohen,
Director -
Brian Powl,
Senior Vice President of Marketing -
Tina Clark Beamon Esq., J.D.,
Chief Compliance Officer -
Dr. Karen E. Potts Ph.D.,
Sr. VP of Regulatory Affairs -
Dr. Ofir Moreno,
Sr. VP of Pharmaceutical Sciences -
Jamie A. Tereschuck,
VP of HR -
David A. Walsey J.D., L.L.M.,
VP of IR & Corp. Communications -
Leaf Ventures Ii, L.P.New L...,
-
Ventures V, Llc Vivo,
-
Leah Rush Cann,
Director -
Thomas M. Zech,
Chief Financial Officer -
William Dodge Rueckert,
Director -
Ventures Vii, Llc Vivo,
-
Christine Anna White,
Director -
Ventures V, Llc Vivo Ventur...,
-
Leaf Ventures Ii, L.P.New L...,
-
Leaf Ventures Ii, L.P.New L...,
-
Ventures Vii, Llc Vivo Vent...,
-
Josiah T El Coronado Holdin...,
-
Leaf Ventures Ii, L.P.New L...,
-
Josiah T Austin,
10% owner -
Bryan Williams,
Director -
Ltd Novogen,
10% owner -
Sujay Kango,
-
Richard G Ghalie,
Chief Medical Officer -
Thomas C Reynolds,
-
Funds Management Lp Anson A...,
-
Funds, Lp Cable Car Capital...,
-
Steven D Wood,
-
James P Flynn,